Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Cash from Financing Activities (2025)

Drugs Made In America Acquisition filings provide 1 years of Cash from Financing Activities readings, the most recent being $130600.0 for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to $130600.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $231.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $231.7 million for FY2025, 133351.97% up from the prior year.
  • Cash from Financing Activities hit $130600.0 in Q4 2025 for Drugs Made In America Acquisition, up from $56003.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $231.4 million in Q1 2025 and bottomed at $56003.0 in Q3 2025.